Esperion Therapeutics (ESPR) 'Significantly Undervalued' Despite Move - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Esperion Therapeutics (ESPR) Continues Surge Higher; Up 14% on Heavy Volume
February 7, 2017 12:51 PM ESTEsperion Therapeutics (NASDAQ: ESPR) continues its recent surge higher after Amgen recently announced positive results from their FOURIER trial that evaluates Repatha (evolocumab), an anti-PCSK9 antibody, in ASCVD patient.
Shares are up 14.3% today on volume that is running 8x the norm. The stock is up about 70% since the Amgen news.
... MoreMedicines Co. (MDCO), Esperion Therapeutics (ESPR) Gain After Amgen Reports Positive Cardiovascular Outcomes from Repatha Study
February 2, 2017 5:19 PM ESTMedicines Co. (NASDAQ: MDCO) and Esperion Therapeutics (NASDAQ: ESPR) gained post-market after Amgen said its FOURIER trial evaluating whether Repatha reduces the risk of cardiovascular events met its primary endpoint. Shares of Novelion Therapeutics (NASDAQ:... More
